Related Experiment Video

Updated: Mar 31, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.8K

Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of

Lingdi Zhao1, Wei Li1, Huiying Zhang1

  • 1Department of Cancer Biotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.

Oncotargets and Therapy
|October 23, 2015
PubMed
Abstract

Insights

Rechallenging with angiogenesis inhibitors (AIs) significantly improves progression-free survival in advanced non-small-cell lung cancer (NSCLC) patients previously treated with bevacizumab. This suggests AIs offer clinical benefits for relapsed NSCLC patients.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Limited data exists on the efficacy of angiogenesis inhibitors (AIs) rechallenge in advanced non-small-cell lung cancer (NSCLC) patients previously treated with bevacizumab.
  • Bevacizumab is a key first-line therapy for advanced NSCLC, but outcomes after progression require further investigation.

Purpose of the Study:

  • To investigate the efficacy of angiogenesis inhibitors (AIs) rechallenge in advanced NSCLC patients who have previously received bevacizumab.
  • To evaluate the impact of AI rechallenge on survival outcomes in this specific patient population.

Main Methods:

  • A systematic literature search was conducted across PubMed, Web of Science, and ASCO meeting abstracts up to December 1, 2014.
  • Eligible studies included prospective randomized controlled trials assessing AIs in advanced NSCLC with prior bevacizumab exposure.
  • Meta-analysis was performed using random or fixed effect models to determine overall survival (OS) and progression-free survival (PFS).

Main Results:

  • Analysis included 452 patients with advanced NSCLC previously treated with bevacizumab.
  • AI rechallenge significantly improved progression-free survival (PFS) compared to non-AI regimens (HR: 0.72, P=0.002).
  • A trend towards improved overall survival (OS) was observed, though not statistically significant (HR: 0.82, P=0.087).

Conclusions:

  • Angiogenesis inhibitor rechallenge demonstrates significant clinical benefit in advanced NSCLC patients who relapsed after first-line bevacizumab-containing chemotherapy.
  • The findings support the consideration of AI rechallenge in this patient subgroup.
  • Further prospective clinical trials are recommended to confirm the role of AI rechallenge in advanced NSCLC.
Keywords:
angiogenesis inhibitorsmeta-analysisnon-small-cell lung cancerrandomized controlled trialsrechallengesecond-line

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562